Wuhan Jiulong Renfu Pharmaceutical Co., Ltd.

Primary objective: To evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects under fasting and fed conditions, using tadalafil tablets (specification: 20 mg) provided by Wuhan Jiulong Renfu Pharmaceutical Co., Ltd. and produced by Chongqing Boteng Pharmaceutical Co., Ltd. as the test preparation and tadalafil tablets (specification: 20 mg, trade name: Cialis®) certified by A. Menarini GmbH and produced by Lilly del Caribe, Inc. as the reference preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects under fasting and fed conditions.

Primary objective: To investigate the pharmacokinetic characteristics of apalutamide tablets (60 mg) owned by Wuhan Jiulong Renfu Pharmaceutical Co., Ltd. and apalutamide tablets (60 mg) owned by Janssen-Cilag International NV in healthy Chinese male subjects after a single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of apalutamide tablets (60 mg) in healthy Chinese male subjects after a single oral administration.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg; produced by Wuhan Jiulong Renfu Pharmaceutical Co., Ltd.) and the reference preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg; produced by Bayer Weimar GmbH & Co. KG) in healthy adult female participants after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. Secondary purpose of the study is to study the safety of the test preparation drospirenone ethinylestradiol tablets (II) (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg) and the reference preparation drospirenone ethinylestradiol tablets (specifications: drospirenone 3 mg and ethinylestradiol 0.02 mg) in healthy adult female participants.